This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CUR Neuralstem (CUR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Neuralstem Stock (NASDAQ:CUR) Get Neuralstem alerts:Sign Up Key Stats Today's Range$1.86▼$2.0050-Day Range$0.67▼$1.5252-Week Range$1.10▼$13.78Volume1.84 million shsAverage Volume236,278 shsMarket Capitalization$3.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland. Read More Receive CUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuralstem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUR Stock News HeadlinesWall Street Breakfast Podcast: Gold Soars Past $4,400December 22, 2025 | seekingalpha.comAguas Da Curia Share Price (CUR.LS)November 25, 2023 | lse.co.ukIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.August 3 at 1:00 AM | Banyan Hill Publishing (Ad)XAUUSD:CUR Gold Spot PriceAugust 22, 2023 | seekingalpha.com4 Biotech Stocks Under $10 Moving HigherJuly 20, 2023 | thestreet.comXPTUSD:CUR Platinum Spot PriceJune 28, 2023 | seekingalpha.comXAUUSD:CURMay 16, 2023 | seekingalpha.comNovAccess Global : Announces Fireside Chat with Board Member Perspectives - Marketscreener.comOctober 20, 2022 | marketscreener.comMSee More Headlines CUR Stock Analysis - Frequently Asked Questions How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.45) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. Neuralstem had a negative trailing twelve-month return on equity of 170.51% and a negative net margin of 39,417.64%. When did Neuralstem's stock split? Neuralstem's stock reverse split before market open on Thursday, July 18th 2019.The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuralstem investors own include XOMA Royalty (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri AS (TKC), SELLAS Life Sciences Group (SLS) and ACADIA Pharmaceuticals (ACAD). Company Calendar Last Earnings8/14/2019Today8/03/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CUR CIK1357459 Webwww.neuralstem.com Phone301-366-4841FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.93 million Net Margins-39,417.64% Pretax MarginN/A Return on Equity-170.51% Return on Assets-110.16% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual Sales$260 thousand Price / Sales15.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.28Miscellaneous Outstanding Shares2,100,000Free FloatN/AMarket Cap$3.93 million OptionableNot Optionable Beta1.81 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CUR) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
